Literature DB >> 6700945

The effect of repeating full-circumference argon laser trabeculoplasty.

R J Starita, R L Fellman, G L Spaeth, E Poryzees.   

Abstract

Seventeen eyes of 16 patients who were classified as treatment failures following 360 degrees of argon laser trabeculoplasty underwent repeat treatment of the meshwork with the argon laser. Average intraocular pressure was significantly reduced from 22.5 +/- 6.8 to 19.3 +/- 6.1 mm Hg (P less than 0.05). Fifty-three percent of cases had a reduction and 12% had an increase in intraocular pressure of greater than or equal to 3 mm Hg at an average follow-up of 12 weeks. Visual function was not stabilized in 41% of the cases with 29% requiring further glaucoma surgery.

Entities:  

Mesh:

Year:  1984        PMID: 6700945

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  7 in total

1.  Argon laser trabeculoplasty controls one third of patients with progressive, uncontrolled open-angle glaucoma for five years.

Authors:  K A Baez; G L Spaeth
Journal:  Trans Am Ophthalmol Soc       Date:  1991

2.  The role of apraclonidine hydrochloride in laser therapy for glaucoma.

Authors:  A L Robin
Journal:  Trans Am Ophthalmol Soc       Date:  1989

3.  Therapeutic limitations of argon laser trabeculoplasty.

Authors:  A I Fink; A J Jordan; P N Lao; D A Fong
Journal:  Br J Ophthalmol       Date:  1988-04       Impact factor: 4.638

4.  The therapeutic limitations of argon laser trabeculoplasty.

Authors:  A I Fink; A J Jordan; P N Lao; D A Fong
Journal:  Trans Am Ophthalmol Soc       Date:  1985

5.  Repeat selective laser trabeculoplasty.

Authors:  Bryan Kun Hong; Jeffrey C Winer; James F Martone; Martin Wand; Bruce Altman; Bruce Shields
Journal:  J Glaucoma       Date:  2009-03       Impact factor: 2.503

6.  Clinical options for the reduction of elevated intraocular pressure.

Authors:  Laura Crawley; Sohaib M Zamir; Maria F Cordeiro; Li Guo
Journal:  Ophthalmol Eye Dis       Date:  2012-04-30

7.  Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial.

Authors:  Tony Realini; Gus Gazzard; Mark Latina; Michael Kass
Journal:  J Glaucoma       Date:  2021-07-01       Impact factor: 2.290

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.